Zoetis Inc. (ETR:ZOE)
Germany · Delayed Price · Currency is EUR | Market Cap | 26.62B -55.8% |
| Revenue (ttm) | 8.27B +2.9% |
| Net Income | 2.32B +7.4% |
| EPS | 5.30 +11.0% |
| Shares Out | n/a |
| PE Ratio | 11.48 |
| Forward PE | 10.64 |
| Dividend | 1.77 (2.75%) |
| Ex-Dividend Date | Apr 20, 2026 |
| Volume | 4,323 |
| Average Volume | 2,544 |
| Open | 65.66 |
| Previous Close | 64.64 |
| Day's Range | 64.30 - 66.66 |
| 52-Week Range | 64.28 - 150.52 |
| Beta | 0.86 |
| RSI | 11.99 |
| Earnings Date | Aug 5, 2026 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial numbers in USD Financial StatementsNews
Zoetis price target lowered to $99 from $130 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $99 from $130 and keeps a Neutral rating on the shares.
Zoetis price target lowered to $105 from $130 at Stifel
Stifel lowered the firm’s price target on Zoetis (ZTS) to $105 from $130 and keeps a Hold rating on the shares.
Zoetis price target lowered to $130 from $190 at JPMorgan
JPMorgan lowered the firm’s price target on Zoetis (ZTS) to $130 from $190 and keeps an Overweight rating on the shares.
Morning Movers: Planet Fitness and Zoetis sink after quarterly results
Futures are higher this morning, helped by another sharp decline in oil prices on optimism around a potential U.S.-Iran framework agreement. Crude dropping back toward the low-$90s is relieving pressu...
Zoetis Q1 ‘worse than it seems,’ says Stifel
Stifel notes that Zoetis (ZTS) Q1 organic operational revenue growth was flat versus the firm’s forecast for 2.4% growth and the Street’s 2.2% expectation. However, Zoetis’ results benefited from a…
Zoetis reports Q1 adjusted EPS $1.53, consensus $1.62
Reports Q1 revenue $2.3B, consensus $2.3B. “The first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting i...
Zoetis sees FY26 adjusted EPS $6.85-$7.00, consensus $7.03
Sees revenue $9.68B-$9.96B, consensus $9.89B.
Zoetis Is Today's Worst S&P 500 Stock. Here's Why.
The animal-health company missed first-quarter earnings estimates.
Zoetis Earnings Call Transcript: Q1 2026
Q1 2026 saw flat organic revenue and 1% adjusted net income growth, with strong international and livestock performance offsetting U.S. and companion animal declines. Guidance for 2026 expects 2%-5% organic revenue growth amid ongoing macro and competitive headwinds.
Zoetis Announces First Quarter 2026 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the first quarter of 2026. The com...
Zoetis price target lowered to $130 from $136 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $130 from $136 and keeps a Neutral rating on the shares. The Q1 earnings outlook is cautious amid softer macro…
Zoetis initiated with a Buy at Citi
Citi initiated coverage of Zoetis (ZTS) with a Buy rating and $145 price target Citi also opened an “upside 90-day catalyst watch” on Zoetis, saying Solensia will return to growth…
Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Pec...
Zoetis Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Revenue growth is projected at 3%-5% for 2026, led by parasiticides and supported by strong livestock performance. Long-acting therapies and new franchises in renal, oncology, and cardiology are expected to drive future growth, while AI and field team restructuring enhance operational efficiency.
Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital ...
Zoetis Transcript: Barclays 28th Annual Global Healthcare Conference
2025 saw strong growth, led by livestock and international diversification, despite U.S. consumer pressures and competitive launches. Triple combination parasiticides and dermatology remain key growth drivers, with a robust pipeline targeting major unmet needs. Capital allocation focuses on investment, M&A, and shareholder returns.
Zoetis Transcript: Leerink Global Healthcare Conference 2026
Pet health spending remains resilient, with growth in emergency and preventive care, while innovative products like Trio and Key Derm drive expansion through high satisfaction and compliance. The pipeline is robust, targeting kidney disease and OA pain, and capital allocation prioritizes R&D, M&A, and shareholder returns.
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will participate in fireside...
Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis to acquire animal genomics business from Neogen, strengthening the company's leadership in Precision Animal Health.
Zoetis Transcript: BofA Securities Animal Health Summit
Solid 2025 results and prudent 2026 guidance reflect resilience amid competition and macro headwinds. Calendar reporting will shift to a synchronized year in 2026, with recasted financials for comparability. Product differentiation, innovation pipeline, and omni-channel strategy support continued growth.
Zoetis to Participate in the Bank of America Securities 2026 Animal Health Summit
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m...
Zoetis forecasts strong 2026 profit, revenue on steady pet‑medicine demand
Zoetis on Thursday forecast 2026 adjusted profit and revenue above Wall Street estimates, as demand across its companion-animal portfolio and resilient international markets helped offset softer trend...
Zoetis Earnings Call Transcript: Q4 2025
Delivered 6% organic revenue and 7% adjusted net income growth in 2025, led by international and livestock segments. 2026 guidance targets 3%-5% organic revenue growth amid ongoing macro and competitive pressures, with continued investment in innovation and disciplined capital allocation.